Proteolysis targeting chimera (PROTAC) technology has recently gained a tremendous momentum for its promise to discover and develop an entirely new type of medicines by inducing targeted protein degradation. Our laboratory has employed the PROTAC technology to discover and develop small-molecule degraders to target a large number of proteins, including those undruggable targets. In this lecture, I will present our latest research in this area and discuss the opportunities and challenges in the discovery and development of PROTAC small-molecule degraders for the treatment of human cancers.
